SJ0043 101ST GENERAL ASSEMBLY

SJ0043 LRB101 11737 MST 58399 r

SENATE JOINT RESOLUTION

WHEREAS, The human papillomavirus (HPV) is the most common sexually transmitted virus in the United States; nearly 14 million people become infected each year; and

WHEREAS, HPV causes approximately 33,700 cases of HPV-associated cancers each year, including cervical, anal, and oropharyngeal cancers; and

WHEREAS, The 9-valent HPV vaccine protects against nine types of HPV infection; and

WHEREAS, Within six years of vaccine introduction in 2006, there was a 64% decrease in HPV in women ages 14 to 19 years, and 34% among females ages 20 to 24 years; and

WHEREAS, The HPV vaccine was thoroughly tested for safety before being licensed and released and continues to be monitored by the Centers for Disease Control and Prevention and the Food and Drug Administration; and

WHEREAS, There have been no serious safety concerns linked to the vaccine; and

WHEREAS, The American Academy of Pediatrics and the Advisory Committee on Immunization Practices recommend two doses of the HPV vaccine for males and females ages 11-12; the vaccine is approved for men and women through age 45; and

WHEREAS, in Illinois, only 50 percent of males and females ages 13 to 17 years were up to date on HPV vaccination in 2017; therefore, be it

RESOLVED, BY THE SENATE OF THE ONE HUNDRED FIRST GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, THE HOUSE OF REPRESENTATIVES CONCURRING HEREIN, that we encourage adolescents in Illinois to receive the HPV vaccine to protect themselves against HPV infection and HPV-related cancers.